entX’s Nuclear Medicine business, IsoMedica, involves developing process technology for the separation and recovery of valuable isotopes from unconventional sources, including low level radioactive waste streams, for the production of precursor materials crucial to current and emerging cancer therapy treatments. The benefit for Australian and other global cancer therapy markets is breaking the reliance on existing supply chains in countries with increasing instability from ongoing geopolitical issues. Creating this sovereign supply chain will benefit availability and cost of future cancer treatment.
entX is developing processes and technologies to feed the exponential growth of the Theragnostic and Targeted Alpha Therapy cancer treatment markets.
177-Lu Supply Chain
Following promising results from early-stage concept development, technology considerations around process design are underway with an aim to deliver a prototype demonstrator targeted for early 2025.
212-Pb Supply Chain
Efforts encompass early-stage concept development and design for the extraction and purification of 228-Ra and 228-Th. With a commitment to innovation and precision, entX aims to deliver a comprehensive process design and demonstration plant, in partnership with Tellus Holdings Ltd, by late 2025.
